In8Bio (INAB) Retained Earnings (2020 - 2026)
In8Bio (INAB) posted Retained Earnings of -$146.2 million for Q1 2026, down 3.61% sequentially from -$141.1 million in Q4 2025, and down 14.92% YoY from -$171.8 million in Q1 2025.
In8Bio (INAB) Retained Earnings (2020 - 2026) Analysis & Trends
In8Bio has reported Retained Earnings for 7 years, with the latest figure at -$146.2 million in Q1 2026.
- Quarterly Retained Earnings fell 14.92% year-over-year to -$146.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$146.2 million (down 14.92% YoY) and the FY2025 annual result came in at -$141.1 million, down 203.65% from the prior year.
- Retained Earnings declined to -$146.2 million in Q1 2026 per INAB's latest filing, from -$141.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $149.3 million in Q3 2025 and troughed at -$146.2 million in Q1 2026.
- A 5-year average of $15.7 million and a median of $72.6 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 409.5% in 2022, then sank 227.46% in 2025.
- Over 5 years, Retained Earnings stood at -$61.2 million in 2022, then jumped by 289.75% to $116.2 million in 2023, then gained by 17.2% to $136.1 million in 2024, then plunged by 203.65% to -$141.1 million in 2025, then fell by 3.61% to -$146.2 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$146.2 million, -$141.1 million, and $149.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | In8Bio | 24.14 Mn | 24.14 Mn | - | 169.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 169.32 Mn |
| Mar 31, 2026 | -146.19 Mn |
| Dec 31, 2025 | -141.10 Mn |
| Sep 30, 2025 | 149.33 Mn |
| Jun 30, 2025 | -132.30 Mn |
| Mar 31, 2025 | -127.21 Mn |
| Dec 31, 2024 | 136.13 Mn |
| Sep 30, 2024 | 124.08 Mn |
| Jun 30, 2024 | -108.41 Mn |
| Mar 31, 2024 | 99.80 Mn |
| Dec 31, 2023 | 116.15 Mn |
| Sep 30, 2023 | 101.38 Mn |
| Jun 30, 2023 | 98.25 Mn |
| Mar 31, 2023 | -68.74 Mn |
| Dec 31, 2022 | -61.21 Mn |
| Sep 30, 2022 | 82.98 Mn |
| Jun 30, 2022 | 72.58 Mn |
| Mar 31, 2022 | 71.67 Mn |
| Dec 31, 2021 | 70.87 Mn |
| Sep 30, 2021 | -26.84 Mn |